Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Hereditary Sensory and Autonomic Neuropathies × volagidemab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hyperglycemia 2 Lymphoma 1 Hereditary Sensory and Autonomic Neuropathies 1 Breast Neoplasms 1

Interventions

duvelisib 2 volagidemab 1 pembrolizumab 1 palbociclib 1 olaparib 1 obinutuzumab 1 lorlatinib 1 gedatolisib 1 encorafenib 1 chiauranib 1 capivasertib 1 binimetinib 1 berzosertib 1 Radiotherapy 1 PX-866 1 NVP-BKM120 1 Letrozole 1 Fulvestrant 1 Everolimus 1 Cetuximab 1 CYH33 1 BAY 1895344 1 AZD1390 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04330625 2022-11-08

Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

Duke University

Phase 1 Terminated

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡